MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
2023: Top 20 Genomics Companies in the World
Beam Therapeutics Inc. (NASDAQ: BEAM)*
Organization & Developments: Beam Therapeutics
Parents
Beam Therapeutics Inc. (NASDAQ: BEAM)*
Children
*Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company developing precision genetic medicines through the use of base editing.
*Beam’s proprietary base editors create precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA.
2019: Beam Therapeutics Announces Collaboration and Exclusive License Agreement with Prime Medicine for Prime Editing Technology
2019: Under the agreement, Beam has the exclusive right to develop prime editing technology for the creation or correction of any single-base transition mutations, as well as for the treatment of sickle cell disease, both of which Beam is already pursuing with its base editing technology.
2020: Beam Therapeutics: Early Stage Gene Editing Company With Cutting Edge Technology
2021: Beam Me Up, Scotty
2022: Beam Therapeutics Announces FDA Clinical Hold on BEAM-201 IND Application
2022: Beam Therapeutics: Expected To Boost Pipeline Development Into 2023_ seekingalpha.com
2022: Beam Therapeutics: Now Is Not The Right Time To Own)_seekingalpha.com
2022: Buy Beam Therapeutics For 2023_ seekingalpha.com
2023: Base Editing Leader With Major Catalyst Next Year (NASDAQ:BEAM)
2023: Beam lays off 20% of staff and culls CAR-T work to save cash
2023: Beam Therapeutics: Rich In Cash, Poor In Punctuality (Rating Downgrade)
2023: Beam Therapeutics: Sale Of Rights To Verve's In Vivo Candidates An Odd Decision
2024: Beam hits hemoglobin goal in first base editing clinical data, reports death tied to conditioning drug
2024: Beam Therapeutics Reports Pipeline Updates and Second
2024: Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A Watch
2024: Beam Therapeutics: Still Holding Fast To Generous Valuation, Still Not A Buy
2024: Pioneering Genetic Medicine with CRISPR Technology
2024: Sickle cell patient dies in Beam study of base editing therapy
2024: Vertex, Beam Report SCD Cell and Gene Therapies Advances at ASH 2024
2025: Beam base editing therapy gets ‘proof of concept’ in rare lung disease
2025: Beam Therapeutics: A Cautious Hold On A Base Editing Pioneer
2025: Beam Therapeutics: Single-Base Editing Seems To Work
2025: Beam Therapeutics: Too Expensive For Me, But Watch For Important Catalysts
2025: Upgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene Therapy
2026: Beam Therapeutics Inc. (BEAM) Presents at European Respiratory Society (ERS) Congress - Slideshow
Jumps
*Key People: Beam Therapeutics
Finance & Acquisitions: Beam Therapeutics